文献速递复苏、休克与脓毒症创伤与烧伤

「我的死讯被严重夸大」:大量输血中徒劳性切点的评估

The reports of my death are greatly exaggerated: An evaluation of futility cut points in massive transfusion.
PubMed 文献 · J Trauma Acute Care Surg · 2023-05-01
一句话结论首批4小时内输血>50 U的创伤患者30天生存率可达31%,>100 U后仍有15%–25%生存,不应仅凭高输血量判定徒劳。

本研究纳入2017年11月至2021年10月院前或急诊科接受紧急发放血制品的成人创伤患者2299例(排除到院30分钟内死亡),按首批4小时内输血总量分为≤50 U组(2043例)和>50 U组(256例),并比较接受全血与仅成分输血者的30天生存。>50 U组30天生存率为31%,低于≤50 U组的79%(p<0.05);接受全血者(n=1291)较仅成分输血者(n=1008)生存 odds 增加43%(95%CI 1.09–1.87,p=0.009),在输血量>50 U时30天生存率更高。作者结论:首批4小时内输血>50 U者生存率可达50%–60%,>100 U后仍有15%–25%,不应仅凭高输血量宣布徒劳。

要点

  • 首批4小时内输血>50 U的成人创伤患者30天生存率为31%,≤50 U组为79%(p<0.05)。
  • 接受全血者(n=1291)较仅成分输血者(n=1008)生存 odds 增加43%(95%CI 1.09–1.87,p=0.009)。
  • 输血量>50 U时,接受全血者30天生存率高于仅成分输血者。
  • 作者结论:首批4小时内输血>50 U者生存率可达50%–60%,>100 U后仍有15%–25%,不应仅凭高输血量宣布徒劳。

适用人群与场景

  • 2017年11月至2021年10月收治的成人创伤患者,在院前或急诊科接受紧急发放血制品者;排除到院30分钟内死亡者。

诊断标准与关键阈值

  • 总血制品定义为院前及到院后首批4小时内的红细胞、血浆和全血总量;按≤50 U或>50 U分为两组。
  • 另按是否接受全血或仅接受成分输血分组。

研究设计与关键结果

  • 共2299例符合纳入标准:≤50 U组2043例,>50 U组256例。
  • >50 U组穿透伤比例高于≤50 U组(47% vs. 30%,p<0.05),院前及到院血压更低,院前及急诊科复苏量更大(p<0.05)。
  • >50 U组30天生存率低于≤50 U组(31% vs. 79%,p<0.05)。
  • 接受全血者(n=1291)较仅成分输血者(n=1008)生存 odds 增加43%(95%CI 1.09–1.87,p=0.009),且在输血量>50 U时30天生存率更高。
  • 作者报告首批4小时内输血>50 U者生存率可达50%–60%,>100 U后仍有15%–25%。

证据类型、等级与局限

  • 证据类型:治疗/管理类研究,证据等级 Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管负责任的血液管理至关重要,但不应仅凭高输血量宣布徒劳。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Following COVID and the subsequent blood shortage, several investigators evaluated futility cut points in massive transfusion. We hypothesized that early aggressive use of damage-control resuscitation, including whole blood (WB), would demonstrate that these cut points of futility were significantly underestimating potential survival among patients receiving >50 U of blood in the first 4 hours.

METHODS: Adult trauma patients admitted from November 2017 to October 2021 who received emergency-release blood products in prehospital or emergency department setting were included. Deaths within 30 minutes of arrival were excluded. Total blood products were defined as total red blood cell, plasma, and WB in the field and in the first 4 hours after arrival. Patients were first divided into those receiving ≤50 or >50 U of blood in the first 4 hours. We then evaluated patients by whether they received any WB or received only component therapy. Thirty-day survival was evaluated for all included patients.

RESULTS: A total of 2,299 patients met the inclusion criteria (2,043 in ≤50 U, 256 in >50 U groups). While there were no differences in age or sex, the >50 U group was more likely to sustain penetrating injury (47% vs. 30%, p < 0.05). Patients receiving >50 U of blood had lower field and arrival blood pressure and larger prehospital and emergency department resuscitation volumes ( p < 0.05). Patients in the >50 U group had lower survival than those in the ≤50 cohort (31% vs. 79%; p < 0.05). Patients who received WB (n = 1,291) had 43% increased odds of survival compared with those who received only component therapy (n = 1,008) (1.09-1.87, p = 0.009) and higher 30-day survival at transfusion volumes >50 U.

CONCLUSION: Patient survival rates in patients receiving >50 U of blood in the first 4 hours of care are as high as 50% to 60%, with survival still at 15% to 25% after 100 U. While responsible blood stewardship is critical, futility should not be declared based on high transfusion volumes alone.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Clements TW, Van Gent JM, Lubkin DE, et al. The reports of my death are greatly exaggerated: An evaluation of futility cut points in massive transfusion. J Trauma Acute Care Surg. 2023. PMID: 37125814. doi:10.1097/TA.0000000000003980

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。